At a glance
- Originator Takeda
- Class Antihyperlipidaemics
- Mechanism of Action Squalene synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 04 Jan 1996 Discontinued-Preclinical for Hyperlipidaemia in Japan (Unknown route)
- 22 Jun 1995 New profile
- 22 Jun 1995 Preclinical development for Hyperlipidaemia in Japan (Unknown route)